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Abstract
Ibalizumab is a humanized monoclonal antibody that binds human CD4—a key receptor for HIV
—and blocks HIV-1 infection. However, HIV-1 strains with mutations resulting in loss of an N-
linked glycan from the V5 loop of the envelope protein gp120 are resistant to ibalizumab.
Previous structural analysis suggests that this glycan fills a void between the gp120 V5 loop and
the ibalizumab L chain, perhaps causing steric hindrance that disrupts viral entry. If this void
contributes to HIV-1 resistance to ibalizumab, we reasoned that ‘refilling’ it by engineering an N-
linked glycan into the ibalizumab L chain at a position spatially proximal to gp120 V5 may restore
susceptibility to ibalizumab. Indeed, one such ibalizumab variant neutralized 100% of 118 tested
diverse HIV-1 strains in vitro, including ten strains resistant to parental ibalizumab. These findings
demonstrate that the strategic placement of a glycan in the variable region of a monoclonal
antibody can substantially enhance its activity.
INTRODUCTION
The human immunodeficiency virus type 1 (HIV-1) epidemic continues to spread at an
alarming rate of approximately 2.5 million new cases per year, and a safe and effective HIV
vaccine is still elusive. Currently used strategies to fight the spread of HIV-1 include pre-
exposure prophylaxis (PrEP) using small-molecule antiretroviral drugs1-3 and virus-
inhibiting immunoglobulins4. However, compared to antiviral drugs, HIV-1 neutralizing
antibodies tend to have better in vivo pharmacokinetic profiles in humans. HIV-1-
neutralizing antibodies have shown efficacy in several animal models. For example, passive
administration of anti-envelope (gp120 or anti-gp41) monoclonal antibodies (mAb) such as
b12, 2G12, 2F5, and 4E10 protects rhesus macaques against challenge with simian-human
immunodeficiency virus (SHIV)5, 6. However, mAb-based passive immunization therapy
was considered infeasible for a long time due to the relatively weak potency and/or narrow
breadth of the available HIV-1-neutralizing mAbs. However, recently identified human anti-
HIV mAbs including VRC017, PG98, 3BNC1179, PGT antibodies10, 11, NIH45-46G54W12,
and 10E813 with much greater breadth and potency increase enthusiasm about the prospect
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tof using mAb for PrEP or passive immunization. Indeed, compared to first-generation
HIV-1-neutralizing mAb, much lower concentrations of one such next-generation antibody
protected of monkeys from virus challenge11. In addition, AAV-based expression of VRC01
in a humanized mice model led to successful prophylaxis against HIV-1 infection14.
Nevertheless, with the exception of 10E8, most of these next-generation mAbs only
neutralize around 70% to 90% of circulating HIV-1 strains, even at concentrations as high as
50 μ g/mL.
PrEP strategies may also use mAbs specific for the HIV-1 receptors CCR515 and CD416-19,
as such mAbs also show potent and broad inhibitory activity against HIV-1. For example,
ibalizumab (formerly TNX-355) is a humanized IgG4 mAb that blocks HIV-1 entry by
binding to human CD4 with high affinity17-21. Ibalizumab inhibits entry of a diverse
spectrum of clinical and laboratory-adapted HIV-1 isolates, including CCR5-tropic and
CXCR4-tropic strains from multiple subtypes. Mutagenesis22 and structural studies23
demonstrated that ibalizumab binds CD4 mainly by direct contacts with the BC-loop (AA
121-125) in domain 2 (D2) of CD4. Additional contacts include those between residues
164-165 (the short FG loop in D2) of CD4 and the ibalizumab H chain, as well as between
the Ser79 and Glu77 (in the EF loop in D1) of CD4 and the ibalizumab L chain. Located at
the interface between D1 and D2 of CD4, the ibalizumab epitope is positioned on the
opposite side from the region of CD4 that engages HIV-1 gp120 or major histocompatibility
complex class II (MHCII) (Fig. 1). Consistent with these findings, ibalizumab does not
inhibit binding of CD4 to monomeric gp12016. Thus, ibalizumab is thought to inhibit a post–
HIV-1 attachment step required for virus entry. In Phase 1, Phase 2a, and Phase 2b clinical
trials in HIV-1 patients, ibalizumab treatment resulted in substantial reductions (~1 log) in
viral load and significant increases in CD4+ T-cell counts, without serious immunologic
impairments or adverse effects17, 19. Ibalizumab is now awaiting a Phase 3 clinical trial to
examine its efficacy in HIV-1 patients with multi-drug resistant viruses in need of salvage
antiretroviral therapy. We are also exploring the feasibility of using ibalizumab and
ibalizumab variants for the purpose of HIV-1 prevention.
Unfortunately, HIV-1 strains with reduced susceptibility to ibalizumab (in terms of
ibalizumab effects on virus infectivity) were isolated from HIV-1 patients who experienced
a rebound in viral load after the addition of ibalizumab to failing antiretroviral drug
regimens24. In most of these cases, a much reduced plateau of maximum percentage of
inhibition (MPI) in the dose-response curve was observed17,24. In other words, complete
virus inhibition cannot be achieved despite increasing antibody concentrations. Such
flattening of the virus-inhibition curve is characteristic of the resistance profile for a
noncompetitive inhibitor of HIV-1 entry. Further evaluation of ibalizumab-resistant viruses
indicated that reduced susceptibility to ibalizumab is conferred by the loss of one or two
potential N-linked glycosylation sites (PNGS) in the V5 loop of HIV-1 gp12024. Indeed,
among unselected wild-type HIV-1 isolates, there is a strong correlation between the number
of V5 glycosylation sites and ibalizumab susceptibility25. Moreover, site-directed
mutagenesis confirmed that the loss of glycan at the V5 N-terminus was the major
contributor to ibalizumab resistance25.
Here, based on structural modeling we propose that a glycan on the N-terminus of gp120
fills a vacant space between the L chain of ibalizumab and gp120 V5, and that ibalizumab’s
effect on HIV-1 entry is sterically mediated by the mass effect of this glycan. We confirm
this hypothesis by creating a panel of ibalizumab mutants with PNGS at various positions in
the L chain and measuring their ability to neutralize HIV-1 infectivity in vitro. Indeed,
ibalizumab mutants bearing a glycan located in close proximity to V5 in the ibalizumab-
CD4-gp120 complex efficiently neutralized HIV-1. These ibalizumab mutants also
neutralized HIV-1 strains that are resistant to wild-type ibalizumab. One particular
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tibalizumab mutant, LM52, neutralized 100% of the tested 118 HIV-1 isolates at a potency
more than 10-fold higher than wild-type ibalizumab judging by the geometric mean IC80,
the antibody concentration required to neutralize 80% of infection. The results of this study
suggest that ibalizumab blocks HIV-1 entry through a steric hindrance mechanism, and
provide an example of how a strategic placement of an N-linked glycosylation site can be
used to improve the activity of a mAb. In addition, to our knowledge there is no previous
report of a monospecific mAb of natural architecture reported to neutralize the infectivity of
100% of the HIV-1 strains tested.
RESULTS
Design of ibalizumab variants
Studies of ibalizumab-resistant HIV-1 strains revealed that resistance is mainly conferred by
the loss of glycan(s) from the V5 loop of HIV-1 Env gp12024, 25. To further explore the role
of V5 glycosylation in ibalizumab susceptibility, we modeled the interactions between
gp120, CD4 and ibalizumab using the structures reported to the Protein Data Bank
(accession number 2NXY and 3O2D). The V5 N-terminal glycan is situated closest to the
ibalizumab L chain (Fig. 1A), while the V5 C-terminal glycan is further away from
ibalizumab (Fig. 1B). This model raises the possibility that the fit of the N-terminal glycan
into the space between gp120 and ibalizumab exerts a mass effect on gp120, thereby
disrupting its conformational changes (twists and turns) that are essential for HIV-1 entry
into the target cell. This model also suggests that introduction of a similarly sized glycan
into the ibalizumab L chain may boost its ability to inhibit entry of HIV-1 strains that have
lost their V5 N-terminal glycan.
We therefore introduced PNGS into residues (30E, 52, 53, 54, 60, 65, 67, and 76) in the
variable region of the ibalizumab L chain that are proximal to the V5 loop of gp120. These
ibalizumab L chain mutants (LMs) were constructed, sequenced, and transfected into 293A
cells to produce mutant proteins. We purified the variant mAbs by protein-A agarose
chromatography, and analyzed them by SDS-PAGE (Fig. 2A). Yields of LMs from transient
expression in 293A cells were comparable to those of wild-type ibalizumab (data not
shown). A slightly bigger L chain was observed in each of the LMs compared to the wild-
type L chain. To confirm that the larger sizes are due to glycosylation, LMs 30E, 52, and 53
were treated with PNGase F under denaturing conditions and analyzed by SDS-PAGE (Fig.
2B). As expected, the sizes of the L chains of these variants post-PNGase F treatment were
decreased to the size of the wild-type. We next used mass spectrometry to identify the form
of N-glycans introduced to the L chain of LM52 routinely produced in 293A cells. Over six
forms of complex type N-glycans with 8-12 rings were identified on the L chain, with 80%
of these forms having 9-11 rings (Fig. 2C). Taken together, these data confirmed that N-
linked glycans were introduced into the desired residues of the ibalizumab L chain.
CD4 binding and HIV-1 neutralization by LMs
We next evaluated the kinetics of binding of these ibalizumab LMs to human soluble CD4
(sCD4) by surface plasmon resonance. In a Biacore assay using sCD4 as the analyte, WT
ibalizumab and LMs bound sCD4 with similar binding kinetics. The KD of six of these LMs
bound to sCD4 was in the range of 0.19 nM to 0.8 nM (Table S1), and these numbers were
within 2-fold of the KD of wild-type ibalizumab (0.43 nM). These data showed that the
addition of an N-linked glycan at these select locations in the L chain of ibalizumab did not
markedly affect its ability to bind CD4.
We next explored the HIV-1 neutralizing capacity of the LMs compared to WT ibalizumab.
To this end, we tested the LMs against a panel of HIV-1 viruses that are resistant or partially
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tresistant to ibalizumab, including 3 replication-competent HIV-1 strains (Fig. 3). Using this
panel of ibalizumab-resistant viruses, an average MPI of 75% and IC80 of 1.43 μ g/mL were
observed when WT ibalizumab was tested up to 2 μ g/mL. Markedly improved neutralization
activities were observed for four LMs (LM30E, LM52, LM53, and LM67), with an average
MPI of 91-99% and IC80 of 0.05-0.14 μ g/mL (Fig. 3 and Table S2). Among these, LM52
appears to have the best HIV-1 neutralization potency. Two other variants (LM54 and
LM65) yielded more modest improvement in virus-neutralization activities compared to
ibalizumab. Interestingly, the PNGS in the six LMs that showed improved HIV-1
neutralizing activity are also closer to V5 (459) of gp120 (Table S2 and Figure S1) than the
PNGS in LM60 and LM76, which showed HIV-1 neutralizing activity comparable to those
of WT ibalizumab. Therefore, it seems that positioning the N-glycan closer to V5 improves
the neutralization profile of ibalizumab variants. We note, however, that the orientation of
the glycan, in addition to the distance to V5, may also play a critical role.
Glycan size influences LM52 activity
We next studied whether glycan size influences the improved HIV-1 neutralization activity
of the LMs. We focused on LM52 because of its superior HIV-1 neutralization profile (Fig.
3). To produce a version of LM52 lacking any N-linked glycan, we added tunicamycin26,
which inhibits GlcNAc phosphotransferase, to 293A cells immediately after transient
transfection with the LM52 construct. Similarly, to produce a version of LM52 tagged with
glycans of 10-11 rings (the high Man-type N-glycan Man8GlcNAc2 (Man8) or
Man9GlcNAc2 (Man9)) we added kifunensine27 to 293A cells. Lastly, to produce a version
of LM52 bearing a 7-ring glycan (high mannose (Man)-type N-glycan Man5GlcNAc2
(Man5)), we used N-acetylglucosaminyltransferase I-negative GnT1(−) HEK293S cells28.
As shown by SDS-PAGE, although the addition of kifunensine did not noticeably change
the size of the L chain, addition of tunicamycin or growth in GnT1(−) cells noticeably
reduced the size of the L chain (Fig. 4a). Similarly, the neutralization activities against three
HIV-1 strains were more severely reduced for antibodies produced in the presence of
tunicamycin or in GnT1(−) cells than for the antibody produced in the presence of
kifunensine (Fig. 4B). Thus, stronger HIV-1-neutralizing activity was observed when larger
glycans were present in the L chain at residue 52. Modeling suggests that larger glycans
better fill the space between the L chain and gp120 (Fig. 4C), but the nature of the branching
of the glycan may also affect the HIV-1 neutralizing activity of LM52.
Neutralization breadth and potency of LM52
We then tested the HIV-1 neutralization activity of LM52 against a panel of 118 diverse
HIV-1 viral strains covering 11 clades. LM52 showed significantly improved neutralization
breadth and potency compared to WT ibalizumab in this single-cycle TZM-bl assay (Figure
5 and Table S3). LM52 had no neutralizing activity against the negative control virus
(murine leukemia virus) (Table S3), but it neutralized (as defined by ≥50% inhibition) all
HIV-1 strains tested, compared to 92% of strains for WT ibalizumab. In fact, LM52
neutralized 97% of viruses to ≥95% inhibition, compared to only 31% for WT ibalizumab
(Fig. 5, upper panels). LM52 also exhibited IC50 values of <0.1 μ g/mL for all 118 viruses,
compared to 75% of viruses for WT ibalizumab (Fig. 5, middle panels). Indeed, all of the
viruses were neutralized by LM52 with an IC80 <0.3 μ g/mL, whereas 36% of the viruses
were not neutralized by 80% with WT ibalizumab even at a concentration of 10 μ g/mL (Fig.
5, lower panels).
Overall, the geometric mean IC50 value for LM52 was 14 ng/mL, compared to 74 ng/mL for
WT ibalizumab, and the geometric mean IC80 value for LM52 was 37 ng/mL, compared to
510 ng/mL for WT ibalizumab (Fig. S2). When the viruses were separated into ibalizumab-
sensitive (MPI>80%) and ibalizumab-resistant strains (MPI≤80%), it was evident that the
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tenhanced potency of LM52 was most obvious in ibalizumab-resistant viruses (Fig. S3). In
ibalizumab-resistant viruses, the geometric mean IC80 value for LM52 was 50 ng/mL,
compared to almost 10,000 ng/mL for WT ibalizumab. The potency of LM52 was enhanced
by about 3-fold even in ibalizumab-sensitive viruses.
The improved activity of LM52 was also evident in a plot comparing its HIV-1 strain
coverage across increasing antibody concentrations (Fig. 6). The improvement over WT
ibalizumab was readily apparent, as was its superiority over mAbs (PG9, VRC01, 10E8, and
NIH45-46G54W) known for their broad and potent HIV-1 neutralizing activity. LM52 had
the greatest viral coverage at all concentrations >0.01 μ g/mL and it reached 100% at a
concentration less than 0.1 μ g/mL. Only at concentrations below 0.01 μ g/mL was LM52
coverage inferior to NIH45-46G54W12, a modified version of a human mAb directed to the
CD4-binding site on gp120. It should be noted, however, that ibalizumab inhibits HIV-1
infection by binding to CD4, while VRC01, PG9, 10E8, and NIH45-46 G54W inhibit HIV-1
infection by binding directly to the virus. Nonetheless, regardless of whether these mAbs
bind viral envelope or CD4, they all neutralize HIV-1 infection by blocking viral entry.
Effects of multiple glycans
We next examined the effect of placing two or three glycans in the region of interest in the
ibalizumab L chain. We produced LM30E-52, LM30E-53, and LM52-67 double mutants, as
well as LM30E-52-67 and LM30E-53-67 triple mutants in 293A cells and then purified and
analyzed the antibodies by SDS-PAGE (Fig. S4A). Compared to WT ibalizumab or single
mutant LMs, slightly bigger L chain was observed in each of the double mutants, and an
even bigger L chain was observed in each of the triple mutants. We next explored the HIV-1
neutralization profile of these variant mAbs against a panel of HIV-1 strains known to be
fully or partially resistant to ibalizumab. In general, the double and triple mutants showed
neutralizing activity comparable to that of LM52 (Table S4; Fig. S4B left panel). In fact, the
geometric mean IC80 values suggest that the triple mutants may be slightly less potent
compared to LM52. The only exception noted was for SHIVsf162P3N, a virus more
sensitive to the double and triple mutants than to LM52 (Table S4; Fig. S4B right panel).
Overall, we found no evidence that adding more than one glycan further improves the HIV-1
neutralization profile of LM52 against ibalizumab-sensitive viruses. The improvement to
LM52 by the addition of a second glycan may only be apparent with viruses resistant or
partially resistant to LM52.
Analysis of LM52 polyreactivity
A property common to some HIV-1-neutralizing mAbs is their cross-reactivity with self-
antigens29, 30. Neither LM52 nor ibalizumab bound to HEp-2 epithelial cell extracts (Fig.
S5A) even at concentrations of 10 μ g/mL. In addition, neither LM52 nor ibalizumab showed
reactivity with single-stranded DNA, double-stranded DNA, insulin, lipopolysaccharide, or
keyhole limpet hemocyanin (KLH) (Fig. S5B). Human CD4 protein, the intended target of
ibalizumab, was the only self antigen tested that was recognized by LM52. Thus, we find no
evidence that LM52 is polyreactive with self-antigens.
DISCUSSION
Here we created a superior HIV-1 entry-blocking mAb product in the ibalizumab variant
LM52, which at relatively low concentrations could neutralize all tested HIV-1 strains
tested. To our knowledge, no previous study has reported a mAb demonstrating 100% viral
coverage against a large panel of HIV-1 isolates. The virus-neutralizing properties of LM52
are also evidently superior to those of the WT ibalizumab as well as of a number of the best
anti-Env mAbs reported to date, for example VRC0131, PG98, 10E813, and
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tNIH45-46G54W12. Together with the established safety record of the parental ibalizumab in
humans, these observations suggest that LM52 may be a good candidate for clinical
development for the treatment or prevention of HIV-1. This modified antibody may be
particularly suitable as a long-acting PrEP agent given its expected (based on the known
pharmacokinetic properties of the parental ibalizumab) schedule of monthly administration.
These findings also provide insight into the mechanism of action of ibalizumab. That HIV-1
loses a glycan in the N-terminus of gp120 V5 to become resistant to ibalizumab24, 25 already
suggested the possibility that the ibalizumab mechanism of action is mediated by the glycan
resulting in a steric clash between the antibody L chain and the viral envelope glycoprotein,
thereby sterically disrupting a step in HIV-1 entry. Our observations indicating that a glycan
on the L chain restores the antiviral activity of ibalizumab against ibalizumab-resistant
strains, that positioning this glycan on key residues spatially closest to V5 resulted in
greatest antiviral effect, and that larger glycans conferred larger effects on virus
neutralization collectively support, but do not prove, that ibalizumab blocks HIV-1 infection
via a steric hindrance mechanism.
This study also expands our knowledge about the influence of glycosylation on antibody
activity. Under normal circumstances, an N-linked glycosylation site exists at amino acid
297 in the H chain of all IgG subclasses32, 33. The effect of this glycan has been studied
extensively and found to be essential in mediating proinflammatory activity by maintaining
the H chain in an open conformation required for Fcγ R binding. It has also been noted that
Fc molecules with fucosylated and sialylated glycans have reduced affinities for FcRs
compared with afucosylated or asialylated Fc molecules32, 34. In addition, approximately
20% of human IgGs have PNGS motifs within the variable region34, but the role of N-
glycan in this region has not been thoroughly investigated. Although two studies reported
that the introduction of an N-linked carbohydrate in the variable region resulted in improved
solubility35, 36, no previous study has shown that a glycan strategically placed in the variable
region of an antibody can markedly improve its activity.
MAbs have become a major class of drugs in our therapeutic arsenal, particularly for cancers
and autoimmune disorders. While some antibody drugs mediate their clinical effect by
acting as competitive inhibitors, others act by steric hindrance. For select mAbs in the latter
category, the glycan-addition approach described herein may be adapted to enhance their
functional activity. Guided by structural information on the antigen-antibody complex, it is
conceivable that increasing the bulk at key positions on the antibody could lead to better
activity. Our study provides an example of how structural-activity relationship (SAR) could
be exploited to generate a superior mAb product. It also demonstrates the power of using
SAR to develop improved biological products, as chemists have done for small-molecule
drugs for decades.
METHODS
Cell lines, reagents, and pseudotyped viruses
TZM-bl cells (catalog no. 8129) were obtained through the AIDS Research and Reference
Reagent Program (ARRRP), Division of AIDS, NIAID, NIH. This is a genetically
engineered HeLa cell line that expresses CD4, CXCR4, and CCR5 and contains Tat-
responsive reporter genes for luciferase and β -galactosidase under the control of an HIV-1
long terminal repeat. The Standard Reference Panels of Subtype B HIV-1 Env clones from
acute and early infections and Env-deficient backbone plasmid (SG3Δ Env) were also
obtained through the NIH ARRRP. HIV-1 env pseudotyped viruses were prepared by co-
transfection of 293A cells (Invitrogen) with an Env-expression plasmid and SG3Δ Env.
Recombinant sCD4 comprising the full-length extracellular domain of human CD4 was
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tobtained from Progenics Pharmaceuticals, Inc. (Tarrytown, NY). Ibalizumab protein was
provided by TaiMed Biologics (Irvine, CA). Plasmids pMV1 and pLC, which encode for
ibalizumab H chain and L chain, respectively, were amplified from cDNA and cloned into
pCDNA3.1 (+) (Invitrogen). N-acetylglucosaminyltransferase I-negative GnT1(−) human
embryonic kidney (HEK) 293S cells were obtained from ATCC (catalog no. CRL-3022).
Addition of N-linked glycosylation sites to the ibalizumab L chain
The Asn-Ala-Thr (LM30E, LM53, LM54, LM60, LM65, LM67, and LM76) or Asn-Ser-Thr
(LM52) sequences were introduced by mutagenesis to create ibalizumab L chain mutants.
Mutagenesis was carried out with Quikchange mutagenesis kit (Stratagene, Santa Clara,
VA). LM constructs were sequenced and transiently transfected into HEK293A cells (1:1
ratio of heavy and L chain plasmids) with polyethylenimine (PEI)-DNA complex.
Supernatants were harvested on day 5 post transfection and LM proteins were purified with
a protein-A agarose (Thermo Scientific, Rockford, IL) column. Ibalizumab and LM30E,
LM52, and LM53 were treated with PNGase F (New England Biolabs, Ipswich, MA) under
denaturing conditions, before analysis by SDS-PAGE.
Virus neutralization assay using TZM-bl cells
Neutralization assay was performed based on the method of Wei et al.37 with
modifications38. Briefly, 10,000 cells per well were seeded in a 96-well plate in 100 μ L/well
of DMEM supplemented with 10% fetal bovine serum (D10) and incubated overnight. The
next day, serially diluted ibalizumab or LM proteins were added to the cells and incubated
for 1 h. Then, 200X 50%-tissue-culture-infective-doses (TCID50) of replication-competent
or pseudotyped HIV-1 were prepared in D10 containing DEAE-Dextran (Sigma, St. Louis,
MO) and added to the cells. The cells were incubated for 48 h and β -galactosidase activity
was measured using the Galacto-Star System (Applied Biosystems, Cedarville, OH). The
percentage of inhibition of viral infectivity was calculated as 1 minus the ratio of antibody-
treated wells versus untreated-infected wells multiplied by 100. The IC50 and IC80 values
(the antibody concentrations that confer 50% and 80% neutralization, respectively) were
calculated by a non-linear regression analysis.
Surface plasmon resonance
Binding affinity analyses were performed with a Biacore T3000 optical biosensor (GE
Healthcare, Piscataway, NJ). Immobilization of ibalizumab and all the glycan variants were
performed following the standard amine coupling procedure. Briefly, carboxyl groups on the
sensor chip surface were activated by injection of 35 μ L of a solution containing 0.2 M N-
(3-dimethylaminopropyl)-N-ethylcarbodiimide and 0.05 M Nhydroxysuccinimide at a flow
rate of 5 μ L/minute. Next, ibalizumab or its mutant variant, at a concentration of 2 μ g/mL in
10 mM sodium-acetate buffer, pH 4.5, was allowed to flow over the chip surface at a rate of
10 μ L/minute until the desired level of response units of reacted protein (150-200 RU) was
achieved. After unreacted protein was washed out, excess active ester groups on the sensor
surface were capped by the injection of 35 μ L of 1 M ethanolamine, pH 8.0, at a flow rate of
5 μ L/minute. As background to correct instrument and buffer artifacts, a reference was
generated under the same conditions with omission of the protein ligand. Binding
experiments were performed at 25°C in HBS-EP buffer (0.01 M HEPES, 0.15M NaCl, 3
mM EDTA, 0.005% vol/vol surfactant P20 (GE Healthcare). Binding kinetics were
measured by passing various concentrations of analyte (human sCD4 protein) over the chip
surface at a flow rate of 30 μ L/minute for 3 min. Dissociation of bound analytes was
monitored while the surface was washed for 10 min. Remaining analytes were removed at a
flow rate of 50 μ L/minute with two 30-sec injections of 10 mM glycine-HCl, pH 2.0. For
kinetics data analysis, the kinetic parameters were determined by collectively fitting the
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toverlaid sensograms locally using the BIAevaluation 4.1 software to the 1:1 Langmuir
binding model.
Identification of N-linked glycosylation on LM52
Three micrograms of LM52 protein was dissolved in 50 mM ammonium bicarbonate
(ABC)/50% tetrafluoroethylene and reduced by adding 40 mM dithiothreitol (DTT). After
incubation at 65°C for 1 h, the protein samples were processed for alkylation by adding 40
mM iodoacetamide and incubating at room temperature for 1 h in the dark. The reaction was
quenched by adding 40 mM DTT followed with 1h incubation. Then 25 mM ABC was
added before trypsin digestion. Protein samples were then treated with 0.2 μ g trypsin
(Promega) for overnight. The digested protein samples were dried and re-dissolved with 20
μ L of water before LC-MS/MS analysis. For the assignment for N-glycans on antibodies,
the measured masses of trypsin-digested antibody were compared to a database that
combined predicted tryptic peptides and N-linked glycans. The assigned glycopeptides were
confirmed by the appearance of glycan fragments in MS/MS spectra. For PNGase digestion,
LM52 was treated with PNGase F (New England Biolabs) overnight.
Statistical analyses
Differences in antibody potencies shown in Figures S2 and S3 were assessed by parametric
(Students paired t-test) analyses of 50% and 80% inhibitory concentrations, using GraphPad
Prism v5.03 software. Statistical significance was achieved if P ≤ 0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Model of glycosylation in V5 of HIV-1 gp120, in the context of both CD4 and ibalizumab
(using PyMOL). The complex was modeled by superimposing the structure of D1 and D2 of
CD4 in complex with gp120 (Protein Data Bank accession number 2NXY) onto the same
domains of CD4 in complex with ibalizumab (PDB 3O2D). The glycan (blue) was
introduced at the relevant asparagine by superimposing the asparagine with that of a glycan-
bound asparagine from PDB 3TYG. The heavy and L chains of ibalizumab are shown as
cyan and magenta ribbons, respectively. The first two domains of human CD4 are green,
while HIV-1 gp120 is tan. (A) Man5GlcNac2 at the position 459 of gp120 in the V5 loop (N-
terminal). (B) Man5GlcNac2 at the position of 463 of gp120 in the V5 loop (C-terminal).
Song et al. Page 11
Nat Biotechnol. Author manuscript; available in PMC 2014 May 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 2.
N-linked glycosylation in the L chain of ibalizumab. (A) Ibalizumab L chain mutants (LMs)
were constructed, co-transfected into 293A cells with the WT ibalizumab H chain plasmid,
purified on a protein-A agarose column, and analyzed by SDS-PAGE. WT ibalizumab was
analyzed the same way. (B) Purified WT, LM30E, LM53, and LM52 antibodies were treated
with or without PNGase F at denaturing conditions and analyzed by SDS-PAGE. (C) N-
linked glycoforms on the L chain of LM52 produced in 293A cells were analyzed by mass
spectrometry.
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Neutralization activities of WT ibalizumab and its LMs. Neutralization against a panel of
ibalizumab-resistant or partially ibalizumab-resistant pseudovirus or replication-competent
HIV-1 strains was measured by TZM-bl assay. 96USHIPs9, BK132/GS009, and 96USHIPs7
are replication-competent. CAAN5342.A2-dd and AC10.0.29-dd are site-directed Env
mutants without any PNGS in V5 and are resistant or partially resistant to neutralization by
wild-type ibalizumab. 9015-07 A1 and 1051-D927 are clade B transmitted founder viruses.
The data represent three independent experiments.
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The influence of glycan size on the HIV-1 neutralization activity of LM52. (A) LM52 was
produced in HEK293A cells with or without tunicamycin (LM52-T) or kifunensine (LM52-
K). Alternatively, LM52 was produced in the N-acetylglucosaminyltransferase I-negative
GnT1(−) HEK293S cells (LM52-G). The purified LM52 proteins, together with unmodified
LM52 and WT ibalizumab, were analyzed by SDS-PAGE. (B) Neutralization activities of
ibalizumab and different glycan variants of LM52 against three ibalizumab-resistant
pseudoviruses, as measured in in TZM-bl cells. (C) Depiction (using PyMOL) of the space
filled by glycans of representative conformations and sizes, when tagged on residue 52 of
ibalizumab. Depiction is based on the model generated in Figure 1 and colors are the same.
The 7-ring N-glycan, Man5GlcNac2, was extracted from PDB entry 3TYG. An 11-ring N-
glycan, Man3GlcNac5Fuc, was extracted from PDB entry 3QUM. These results represent
three independent experiments.
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Neutralization of a panel of 118 HIV-1 Env pseudoviruses. Neutralization by LM52 and WT
ibalizumab was measured in a TZM-bl assay. For each virus, black bars indicate maximum
percent inhibition (MPI) when tested at Ab concentrations up to 10 μ g/mL, and the
corresponding IC50 (μ g/mL) or IC80 (μ g/mL). Viruses are ordered by descending MPI for
ibalizumab. Given the large of number of viruses being tested, this experiment was done
only once.
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HIV-1 strain coverage of LM52. Viral coverage of WT ibalizumab, LM52, and PG9, 10E8,
VRC01, and NIH45-46G54W HIV-1 bnAb. LM52 and ibalizumab were tested up to 10 μ g/
mL, while the other monoclonal antibodies were tested up to 50 μ g/mL. The data for PG9,
10E8, VRC01, and NIH45-46G54W were obtained from the published literature7, 8, 12, 13.
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